CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of gynecologic cancers.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to to facilitate the optimal care of patients with gynecologic cancers.
  
  LEARNING OBJECTIVES

  • Consider the FDA approvals of olaparib and niraparib as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer (OC), and counsel patients with and without BRCA mutations regarding appropriate treatment recommendations.
  • Recognize the toxicities associated with the various commercially available PARP inhibitors commonly used in the care of patients with OC, and offer supportive management strategies to minimize and ameliorate these side effects.
  • Understand the importance of microsatellite instability (MSI) testing for patients with gynecologic cancers, and identify the benefits observed with anti-PD-1/PD-L1 antibodies for MSI-high or mismatch repair-deficient disease.
  • Recognize the toxicities associated with pembrolizumab in combination with lenvatinib in patients with advanced, recurrent endometrial cancer, and offer supportive management strategies to minimize and ameliorate these side effects.
  • Consider the potential role of the novel agent tisotumab vedotin in exploiting tissue factor expression in patients with cervical cancer.
  • Assess the toxicities associated with immune checkpoint inhibitors and other novel agents for gynecologic cancers, and offer patients supportive management strategies to minimize and ameliorate these side effects.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  NCPD credit is no longer available for this issue
  
  ONCC/ILNA CERTIFICATION INFORMATION
  The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/ONSGyn2021/ILNA.
  
  ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
  
  FOR SUCCESSFUL COMPLETION
  Audio Program: This NCPD activity consists of an audio component.
  NCPD credit is no longer available for this issue
  
  Video Program: This NCPD activity consists of a video component.
  NCPD credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
  
  Robert L Coleman, MD
  Chief Scientific Officer
  US Oncology Research
  Gynecologic Oncology
  The Woodlands, Texas
  
  Advisory Committee and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, GlaxoSmithKline, ImmunoGen Inc, Janssen Biotech Inc, Merck, Novocure Inc, Roche Laboratories Inc, Takeda Oncology, Tesaro, A GSK Company; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, VBL Therapeutics.
  
  Thomas J Herzog, MD
  Paul and Carolyn Flory Professor
  Deputy Director, University of Cincinnati Cancer Center
  Vice-Chair, Quality and Safety
  Department of Obstetrics and Gynecology
  University of Cincinnati Medical Center
  Associate Director GOG Partners
  Cincinnati, Ohio
  
  Advisory Committee: Aravive Inc, AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Gradalis Inc, GlaxoSmithKline, Merck; Data and Safety Monitoring Board/Committee: Corcept Therapeutics, Incyte Corporation.
  
  Krishnansu S Tewari, MD
  Professor and Division Director
  Division of Gynecologic Oncology
  University of California, Irvine
  Irvine, California
  
  Advisory Committee: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Merck, Tesaro, A GSK Company; Contracted Research (to Institution): Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Iovance Biotherapeutics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Merck, Tesaro, A GSK Company.
  
  Oncology Nurse Practitioners
  
  Paula J Anastasia, MN, RN, AOCN
  GYN Oncology Advanced Practice Nurse
  University of California, Los Angeles
  Los Angeles, California
  
  No relevant conflicts of interest to disclose.
  
  Courtney Arn, CNP
  The James Cancer Hospital and Solove Research Institute
  The Ohio State University
  Columbus, Ohio
  
  No relevant conflicts of interest to disclose.
  
  Kimberly A Spickes, MNSc, RN, APRN, OCN, ACNP-BC
  Nurse Practitioner
  UAMS Division of Gynecologic Oncology
  University of Arkansas for Medical Sciences
  Little Rock, Arkansas
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.
  
  RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Eisai Inc, GlaxoSmithKline and Merck.
  
  Release date: May 2021
  Expiration date: May 2022
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.